We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

By LabMedica International staff writers
Posted on 24 Nov 2025

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. More...

Despite TB infecting 10 million people yearly, the immune mechanisms driving EPTB have remained unclear. A new study now maps the disease’s molecular activity in blood, identifying immune patterns that could lead to targeted therapies and non-invasive diagnostic tests.

In the collaborative study, researchers at the German Center for Infection Research (DZIF), Braunschweig, Germany) used blood samples from EPTB patients for applying multi-omics profiling, including single-cell RNA sequencing, to chart how immune cells communicate during infection.

The approach revealed complex signaling networks involving interferon and interleukin-1 pathways, as well as activation patterns of T cells and natural killer cells. Based on these molecular interactions, researchers identified three distinct “immunotypes,” each representing a unique disease course. The findings, published in Nature Communications, show that these immunotypes expose new biological mechanisms that shape how EPTB develops and progresses.

In addition to immune profiling, the team constructed gene expression–based biomarkers that accurately differentiated extrapulmonary from pulmonary TB. Current diagnosis of EPTB often requires invasive tissue biopsy; however, the newly identified blood signatures could serve as a future non-invasive diagnostic tool. These markers may help clinicians detect EPTB earlier, classify disease severity, and tailor treatments more precisely.

The investigators emphasize that integrating clinical data was essential to correctly interpret molecular findings and connect them to real patient outcomes. Their blood-based biomarker panel is now being validated in the larger mEX-TB clinical study, marking a step towards translation into clinical practice.

"These findings have the potential to substantially advance the diagnosis and treatment of tuberculosis and to facilitate the development of targeted, personalized therapies," said Dr. Thomas Ulas, a bioinformatician at the DZNE.

Related Links:
DZIF


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Hematology Consumables
Bioblood Devices
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image

Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings

Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.